drugset

drugset / Trial / NCT01066364

Colesevelam Versus Placebo in the Treatment of Nonalcoholic Steatohepatitis

NCT01066364 ↗

Phase 2 Completed 59 enrolled University of California, San Diego Daiichi Sankyo · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study is to see if the drug colesevelam is a potential treatment for Nonalcoholic Steatohepatitis(NASH).

Timeline

Start: 2010-02
Primary completion: 2012-02
Completion: 2012-02

Publications

Nedrud MA, Chaudhry M, Middleton MS, Moylan CA, Lerebours R, Luo S, Farjat A, Guy C, Loomba R, Abdelmalek MF, Sirlin CB, Bashir MR. MRI Quantification of Placebo Effect in Nonalcoholic Steatohepatitis Clinical Trials. Radiology. 2023 Mar;306(3):e220743. doi: 10.1148/radiol.220743. Epub 2022 Nov 1.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Colesevelam	Other / unclassified	3.75 g	—

Indications